No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Kopran Limited is an integrated pharmaceutical enterprise specializing in the production and global distribution of both active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers a comprehensive range of drug presentations, such as tablets, capsules, liquid syrups, dry powders, suspensions, injectable solutions, and topical applications. Its diverse therapeutic focus includes antimicrobials (macrolide, antibacterial, anti-infective, antiprotozoal, anthelmintics), neurological treatments (anticonvulsant, central nervous system), cardiovascular medications (anti-hypertensive, anti-thrombotic), metabolic disorder management (antidiabetic), pain relief, gastroenterology (antipeptic ulcer), urological solutions (erectile dysfunction), antiallergics, respiratory care, oncology, and dermatological products (anti-acne). Founded in 1958, Kopran Limited is based in Mumbai, India.
www.kopran.comNo one on the platform currently holds KOPRAN.BO.
No tracked institution reports a position in KOPRAN.BO as of their last filing.
No one on the platform has traded KOPRAN.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.7% | 10.5% | 11.1% | — | — | — |
| Rev. Growth % | 8.2% | 7.2% | ||||
| Profit Margin % | 3.8% | 7.2% | 7.5% | |||
| Free Cash Flow Margin % | -1.5% | -5.4% | -1.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $3.1B | -26.2% | $4.76 | $4.76–$4.76 | — | 1 |
| 2028 | $3.2B | +3.7% | $6.01 | $6.01–$6.01 | — | 1 |
| 2029 | $3.7B | +16.1% | $6.41 | $6.41–$6.41 | — | 1 |
| 2030 | $4.2B | +13.0% | $7.50 | $7.50–$7.50 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| KOPRAN.BOKopran Limited | $260.60 | +4.39% | $12.6B | — |
| ANUHPHR.BOAnuh Pharma Limited | $89.42 | -0.81% | $9.0B | — |
| FERMENTA.BOFermenta Biotech Ltd. | $468.85 | -0.50% | $13.4B | — |
| KILITCH.BOKilitch Drugs (India) Limited | $186.30 | -0.11% | $6.6B | — |
| KILITCH.NSKilitch Drugs (India) Limited | $188.82 | -0.73% | $6.6B | — |
| KPL.BOKwality Pharmaceuticals Limited | $3348.05 | -2.81% |
Source: Financial Modeling Prep · peers by sector/industry
| $34.7B |
| — |
| NGLFINE.BONGL Fine-Chem Limited | $2679.90 | +4.58% | $16.3B | — |